Astellas Pharma - ALPMY Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Astellas Pharma in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ALPMY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALPMY, but not buy additional shares or sell existing shares.
View ALPMY analyst ratings or view top-rated stocks.

Astellas Pharma's stock was trading at $16.27 on January 1st, 2022. Since then, ALPMY shares have decreased by 7.4% and is now trading at $15.07.
View the best growth stocks for 2022 here.

Astellas Pharma saw a drop in short interest in the month of July. As of July 31st, there was short interest totaling 45,100 shares, a drop of 32.5% from the July 15th total of 66,800 shares. Based on an average daily trading volume, of 246,900 shares, the short-interest ratio is currently 0.2 days.
View Astellas Pharma's Short Interest.

Astellas Pharma Inc. (OTCMKTS:ALPMY) released its quarterly earnings data on Tuesday, April, 27th. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of $0.22 by $0.28. The business had revenue of $2.91 billion for the quarter. Astellas Pharma had a net margin of 8.91% and a trailing twelve-month return on equity of 8.62%.

Astellas Pharma (OTCMKTS:ALPMY) pays an annual dividend of $0.27 per share and currently has a dividend yield of 1.78%. The dividend payout ratio is 49.09%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, ALPMY will have a dividend payout ratio of 27.55% next year. This indicates that the company will be able to sustain or increase its dividend.

Astellas Pharma shares split on the morning of Wednesday, April 2nd 2014. The 5-4 split was announced on Friday, March 14th 2014. The newly created shares were payable to shareholders after the closing bell on Tuesday, April 1st 2014. An investor that had 100 shares of stock prior to the split would have 125 shares after the split.

Astellas Pharma trades on the OTCMKTS under the ticker symbol "ALPMY."

Shares of ALPMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALPMY stock can currently be purchased for approximately $15.07.

Astellas Pharma (OTCMKTS:ALPMY) has a market capitalization of $27.67 billion and generates $11.55 billion in revenue each year. The company earns $1.10 billion in net income (profit) each year or $0.55 on an earnings per share basis.

The company employs 15,455 workers across the globe.

Astellas Pharma was founded in 1923.

Astellas Pharma's mailing address is 2-5-1 Nihonbashi-Honcho Chuo-Ku, Tokyo M0, 103-8411. The official website for the company is www.astellas.com. The company can be reached via phone at (133) 244-3000.